GlassScriptPhysician profile
Lei Deng
NPI 1346775251
$11,092.69
in general payments reported to CMS, 2019-2025
14 companies · $476 in 2025
The $476 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $247 · 2023: $449 · 2024: $9,920 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,717 · Travel and Lodging: $2,511 · Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,716.50 |
| Travel and Lodging | $2,510.57 |
| Food and Beverage | $1,618.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,819.95 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $2,443.07 | 2022-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $1,647.19 | 2023-2024 | |
| Seagen INC. | $151.73 | 2023 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Rybrevant |
| Pfizer INC. | $135.00 | 2024 | |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Karyopharm Therapeutics INC. | $126.51 | 2022 | |
| Foundation Medicine, INC. | $124.10 | 2023 | |
| Tempus Ai, INC | $123.49 | 2025 | Xt Cdx |
| Janssen Biotech, INC. | $70.78 | 2025 | Rybrevant |
| Adc Therapeutics America, INC. | $67.59 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $54.66 | 2022 | |
| Genentech USA, INC. | $46.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lei Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.